Company news

Akebia Therapeutics, Inc. news in 2020

Akebia Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal

November 15, 2020

Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates

November 4, 2020

Akebia Therapeutics Announces September 2020 Investor Conference Schedule

September 7, 2020

Akebia Therapeutics Announces Top-Line Results from its PRO2TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis

September 2, 2020

Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan

August 25, 2020

Akebia Reports Second Quarter 2020 Financial Results

August 9, 2020

Akebia Announces Initiation of Investigator-Sponsored Study Evaluating Vadadustat for Prevention and Treatment of ARDS in Patients Hospitalized with COVID-19

July 13, 2020

Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients

June 28, 2020

Akebia Therapeutics Launches AkebiaShares, a Peer-to-Peer Educational Program Series for the Renal Community

June 21, 2020

Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual Congress

June 9, 2020

Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders

May 20, 2020

Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

May 18, 2020

Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® (ferric citrate hydrate) to Treat Adult Patients with Iron Deficiency Anemia in Japan

May 17, 2020

Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

May 10, 2020

Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

May 4, 2020

Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors

April 6, 2020

Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

March 9, 2020

Decks in 2020